Synta Pharmaceuticals Corp.


Madrigal Pharmaceuticals is a biopharmaceutical company dedicated to delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The company aims to halt or reverse liver scarring and has developed the first FDA-approved treatment for MASH. With a focus on innovation, collaboration, and patient-centered care, Madrigal is leading the fight against MASH through extensive research, clinical trials, and community engagement.

Industries

biopharma
biotechnology
medical-device
pharmaceutical

Nr. of Employees

large (251-1000)

Synta Pharmaceuticals Corp.

200 Barr Harbor Drive, Suite 200, West Conshohocken, PA 19428


Patents

Method of synthesizing thyroid hormone analogs and polymorphs thereof

US-11986481-B2

View Details

Methods of treating liver disorders or lipid disorders with a THR-beta agonist

US-11806353-B2

View Details

Methods of synthesizing thyroid hormone analogs and polymorphs thereof

US-11564926-B2

View Details

Combination therapies comprising targeted therapeutics

US-11491145-B2

View Details

Targeted therapeutics

US-11377447-B2

View Details

Methods of treating liver disorders or lipid disorders with a THR-beta agonist

US-11090308-B2

View Details
View All Patents

Products

FDA‑approved oral liver‑directed therapy for adults with MASH

An orally administered, liver‑directed small‑molecule THR‑β agonist therapy approved by the U.S. Food and Drug Administration for treatment of adults with metabolic dysfunction‑associated steatohepatitis (MASH).


Services

Support services for patients including diagnosis assistance, affordability and copay support, educational resources and a dedicated patient support website.

Provision of prescribing information and a channel for medical information requests for healthcare professionals.

Dedicated phone line and processes for reporting adverse events, product quality issues and other safety-related information.

Online application process for sponsorships, patient advocacy grants, R&D grants, medical education grants and investigator‑initiated study funding.

Expertise Areas

  • Clinical trial management for liver disease
  • Small‑molecule drug discovery and liver‑directed pharmacology
  • Regulatory affairs and FDA approval strategy
  • Medical affairs and pharmacovigilance
  • Show More (4)

Key Technologies

  • Small‑molecule THR‑β (thyroid hormone receptor‑β) agonists
  • Liver‑directed pharmacology
  • Oral small‑molecule therapeutics
  • Phase 3 clinical development platforms
  • Show More (5)

News & Updates


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.